Nektar Therapeutics

Nektar Therapeutics Earnings Recaps

NKTR Health Care 2 recaps
Q1 2026 May 11, 2026

Nektar’s shares fell 5.5% following the earnings release, reflecting investor disappointment primarily with cautious outlook and elongated timelines for Phase III data readouts, which delay potential commercialization and revenue generation.

Key takeaways
  • Phase III programs for REZPEG in atopic dermatitis and alopecia areata are on track, with initiation planned by mid-2026 for AD and early 2027 for AA.
  • First Phase III data for atopic dermatitis expected in mid-2028, with a BLA submission targeted for 2029, indicating a lengthy clinical development timeline.
  • Strong clinical data from Phase II showing deepening efficacy and durability in both indications, but no indication of accelerated approval or near-term market access.
  • Company’s financial position is robust with over $1 billion in cash and investments, enabling funding through Q3 2028 without near-term capital concerns.
  • Despite promising mechanistic differentiation and large target markets, investor reaction reflects uncertainty over the pace of advancement and ultimate commercial opportunity timing.
Full recap
Q3 2025 Nov 8, 2025

Nektar Therapeutics reports robust advancements in clinical trials, particularly for rezpegaldesleukin (REZPEG), positioning itself for potential market leadership in atopic dermatitis and alopecia areata.

Key takeaways
  • Successfully advanced REZPEG into the Phase III development stage, targeting moderate to severe atopic dermatitis.
  • Strong preliminary results from the RESOLVE-AD study, showcasing REZPEG's differentiation from existing treatments, particularly for patients with comorbid asthma.
  • Planned presentations of 52-week maintenance data in Q1 and top-line results from alopecia areata studies are expected to further bolster the therapeutic profile.
  • Nektar aims to capture a significant portion of the $1 billion alopecia areata market with REZPEG as a potential first biologic therapy.
  • Upcoming FDA end-of-Phase II meeting anticipated to discuss Phase III plans for REZPEG in atopic dermatitis.
Full recap